Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
1.12.2020 18:01:00 EET | Business Wire | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct acting anti-viral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19”.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit www.rhizen.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005815/en/
Contact information
Samyukta Bhagwati
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals S.A.
Telephone: +41 32 580 0113
Email: corpcomm@rhizen.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physiological data from participating drivers into its broadcast across the season through WHOOP Live. For the first time, fans will be able to see
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 17:16:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed quests can unlock in-game currency, digital items, Xsolla Points, and other rewards delivered through Xsolla Backpack, where players store their digital it
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 16:37:00 EET | Press release
Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. Through practical, science-focused learning, the Academy will create opportunities for local and international professionals across the health and life sciences ecosystem to engage with emerging developments and consider their implications for research, clinical practice, investment and innovation. Drawing on leading local and international expertise, it will support two-way knowledge exchange by bringing global perspectives to
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 16:30:00 EET | Press release
Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, logistics, energy, infrastructure, and building management. A physical AI system extends
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 16:23:00 EET | Press release
Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in September 2026, a new instrument that gives on-chain traders access to liquidity from traditional financial institutions. Swaps ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
